- Home
- FATE vs CNTB Comparison
FATE vs CNTB Comparison
Compare FATE & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | CNTB |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.6M | 128.6M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FATE | CNTB |
|---|---|---|
| Price | $1.34 | $2.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.10 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.5M | 101.7K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.88 | ★ 75.22 |
| EPS | N/A | ★ N/A |
| Revenue | $6,646,000.00 | ★ $26,033,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.05 | $24,617.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $0.51 |
| 52 Week High | $1.94 | $3.28 |
Technical Indicators
Market Signals| Indicator | FATE | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 49.39 |
| Support Level | $0.96 | $2.09 |
| Resistance Level | $1.35 | $2.86 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 20.43 | 20.00 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.